TABLE 3.
Number of patients per 100,000 population receiving a cancer drug through a public drug program for selected high-expenditure cancer drugs
| Drug | Type | Provinces | Mean Number per 100,000 Receiving Drug | Coefficient of Variation | |||||
|---|---|---|---|---|---|---|---|---|---|
| BC | AB | MB | SK | ON | NL | ||||
| Anastrozole | Oral | 60.3 | 28.6 | X | 39.2 | 58.2 | 13.9 | 40.0 | 49.3% |
| Letrozole | Oral | 50.5 | 24.1 | X | 19.8 | 32.5 | 10.3 | 27.4 | 55.3% |
| Docetaxel | IV | 21.3 | 19.5 | 22.5 | 19.7 | 23.7 | X | 21.3 | 8.4% |
| Rituximab | IV | 25.7 | 14.3 | 24.4 | 20.0 | 18.7 | X | 20.6 | 22.1% |
| Gemcitabine | IV | 24.0 | 10.3 | 18.7 | 23.5 | 15.4 | X | 18.4 | 31.2% |
| Capecitabine | Oral | 28.1 | 18.4 | X | 18.3 | 14.3 | 4.8 | 16.8 | 50.2% |
| Trastuzumab | IV | 20.0 | 12.8 | 17.2 | 15.9 | 17.4 | X | 16.7 | 15.8% |
| Irinotecan | IV | 13.6 | 9.2 | 20.7 | 16.2 | 15.3 | X | 15.0 | 27.8% |
| Imatinib | Oral | 8.3 | 6.6 | X | 9.0 | 5.0 | 3.2 | 6.4 | 37.2% |